Form 8-K - Current report:
SEC Accession No. 0001193125-24-230710
Filing Date
2024-10-02
Accepted
2024-10-02 08:11:30
Documents
15
Period of Report
2024-09-30
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d825659d8k.htm   iXBRL 8-K 36305
2 EX-10.1 d825659dex101.htm EX-10.1 1041755
3 EX-99.1 d825659dex991.htm EX-99.1 7101
  Complete submission text file 0001193125-24-230710.txt   1468422

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ebs-20240930.xsd EX-101.SCH 2874
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ebs-20240930_lab.xml EX-101.LAB 17235
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ebs-20240930_pre.xml EX-101.PRE 10829
17 EXTRACTED XBRL INSTANCE DOCUMENT d825659d8k_htm.xml XML 3505
Mailing Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879
Business Address 300 PROFESSIONAL DR GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 241345337
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)